Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease treatments, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025. The results will be released before U.S. financial markets open.
The company, based in South San Francisco, focuses on developing best-in-class therapies aimed at improving patient outcomes in liver and viral diseases. This upcoming financial report will provide insights into the company's performance during Q1 2025.
Aligos Therapeutics (Nasdaq: ALGS), un'azienda biotecnologica in fase clinica specializzata in trattamenti per malattie del fegato e virali, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 6 maggio 2025. I risultati saranno resi noti prima dell'apertura dei mercati finanziari statunitensi.
L'azienda, con sede a South San Francisco, si concentra sullo sviluppo di terapie di eccellenza volte a migliorare gli esiti per i pazienti affetti da malattie epatiche e virali. Questo prossimo rapporto finanziario offrirà una panoramica sulle performance della società nel primo trimestre del 2025.
Aligos Therapeutics (Nasdaq: ALGS), una empresa biotecnológica en etapa clínica especializada en tratamientos para enfermedades hepáticas y virales, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 6 de mayo de 2025. Los resultados se publicarán antes de la apertura de los mercados financieros de EE. UU.
La compañía, con sede en South San Francisco, se enfoca en desarrollar terapias de primera clase destinadas a mejorar los resultados en pacientes con enfermedades hepáticas y virales. Este próximo informe financiero ofrecerá una visión del desempeño de la empresa durante el primer trimestre de 2025.
Aligos Therapeutics (나스닥: ALGS)는 간 및 바이러스 질환 치료에 특화된 임상 단계 바이오텍 기업으로, 2025년 1분기 재무 실적 발표를 2025년 5월 6일 화요일로 예정하고 있습니다. 실적은 미국 금융 시장 개장 전에 발표될 예정입니다.
본사는 사우스 샌프란시스코에 위치해 있으며, 간 및 바이러스 질환 환자들의 치료 결과를 개선하기 위한 최고 수준의 치료법 개발에 주력하고 있습니다. 이번 재무 보고서는 2025년 1분기 동안 회사의 성과에 대한 통찰을 제공할 것입니다.
Aligos Therapeutics (Nasdaq : ALGS), une société biotechnologique en phase clinique spécialisée dans les traitements des maladies hépatiques et virales, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 6 mai 2025. Les résultats seront publiés avant l'ouverture des marchés financiers américains.
Basée à South San Francisco, l'entreprise se concentre sur le développement de thérapies de premier ordre visant à améliorer les résultats pour les patients atteints de maladies hépatiques et virales. Ce prochain rapport financier offrira un aperçu des performances de la société au cours du premier trimestre 2025.
Aligos Therapeutics (Nasdaq: ALGS), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Behandlungen von Leber- und Viruskrankheiten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 6. Mai 2025, geplant. Die Ergebnisse werden vor Öffnung der US-Finanzmärkte veröffentlicht.
Das Unternehmen mit Sitz in South San Francisco konzentriert sich auf die Entwicklung erstklassiger Therapien, die darauf abzielen, die Behandlungsergebnisse von Patienten mit Leber- und Viruskrankheiten zu verbessern. Der bevorstehende Finanzbericht wird Einblicke in die Leistung des Unternehmens im ersten Quartal 2025 geben.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the impact of global events and other macroeconomic conditions on the Aligos business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
FAQ
When will Aligos Therapeutics (ALGS) release Q1 2025 earnings?
What type of company is Aligos Therapeutics (ALGS)?
Where is Aligos Therapeutics (ALGS) headquartered?
Which stock exchange lists Aligos Therapeutics (ALGS)?
